Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph P Insinga

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Immunotherapy|November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USAMin Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
Pharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
Journal of Medical Economics|July 14, 2025
Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in CanadaSylvi Nguyen, Elizabeth Wehler, Chloe Langevin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2010
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young womenRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Pharmacoeconomics - Open|September 19, 2019
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong KongHerbert H Loong, Carlos K H Wong, Linda Kam Suet Leung, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 9, 2011
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearanceRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Immunotherapy|November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USAMin Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
Pharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
Journal of Medical Economics|July 14, 2025
Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in CanadaSylvi Nguyen, Elizabeth Wehler, Chloe Langevin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2010
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young womenRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Pharmacoeconomics - Open|September 19, 2019
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong KongHerbert H Loong, Carlos K H Wong, Linda Kam Suet Leung, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 9, 2011
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearanceRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Pageof 5